KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2025)

Acadia Pharmaceuticals (ACAD) has 7 years of Operating Leases data on record, last reported at $40.6 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 3.53% year-over-year to $40.6 million; the TTM value through Dec 2025 reached $40.6 million, down 3.53%, while the annual FY2025 figure was $40.6 million, 3.53% down from the prior year.
  • Operating Leases reached $40.6 million in Q4 2025 per ACAD's latest filing, down from $44.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $60.6 million in Q1 2021 and bottomed at $40.6 million in Q4 2025.
  • Average Operating Leases over 5 years is $48.7 million, with a median of $47.2 million recorded in 2024.
  • Peak YoY movement for Operating Leases: skyrocketed 894.76% in 2021, then dropped 6.11% in 2022.
  • A 5-year view of Operating Leases shows it stood at $56.1 million in 2021, then fell by 6.11% to $52.7 million in 2022, then decreased by 5.54% to $49.8 million in 2023, then fell by 15.55% to $42.0 million in 2024, then fell by 3.53% to $40.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $40.6 million in Q4 2025, $44.6 million in Q2 2025, and $44.6 million in Q1 2025.